American Regent, Inc. purchased PharmaForce, Inc. (Columbus, OH) on December 29, 2009 and is pleased to announce the addition of Clonidine HCl Injection to its product line.

Click here to download the Press Release

Click here for prescribing information

 American Regent, Inc. purchased PharmaForce Inc. (Columbus, OH) on December 29, 2009 and is pleased to announce that Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP is now available under the American Regent label with a new NDC.

Click here to download the Press Release

Click here for prescribing information

 Luitpold Pharmaceuticals, Inc., a New York based U.S. Company of Daiichi-Sankyo Co., Ltd. (Corporate Headquarters: Tokyo, Japan) and PharmaForce, Inc., (Columbus, Ohio, USA), a privately-held fully-integrated specialty injectable pharmaceutical company, announced today that PharmaForce has been acquired by Luitpold.

Click here to download the Press Release

PharmaForce, Inc. today received FDA approval for Nicardipine Hydrochloride Injection 2.5 mg/mL.

PharmaForce Inc. today received FDA approval for first generic of Clonidine Hydrochloride Injection 100 mcg/mL and 500 mcg/mL.

COLUMBUS, OH - July 31, 2009 - PharmaForce, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP, a generic version of Schering Corporation’s Celestone® Soluspan®.
 
PharmaForce’s product is manufactured in the USA and is marketed in a 6 mg/mL (3 mg base betamethasone/mL; 3 mg/mL betamethasone acetate), 5mL vial dosage form.
 
Shipment of this product has commenced and is available through wholesalers and distributors.
 
“PharmaForce is proud to be providing the healthcare community with this first generic equivalent of Celestone® Soluspan®,” said Nicholas Uchyn, Vice President of Sales. 
 
About PharmaForce, Inc.
PharmaForce, Inc., founded in 1999, is a privately held specialty pharmaceutical company that develops, manufactures, and distributes pharmaceutical products. PharmaForce specializes in injectable, ophthalmic and otic products with more than 35 FDA approved medicines as well as over 30 additional products in development.
 
For more information about Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension and PharmaForce, Inc., please visit: www.pharmaforceinc.com.
 
Please refer to www.pharmaforceinc.com for full prescribing information.
Celestone® Soluspan® is a registered trademark of Schering Corporation.
 
 
Media Contact:
Nicholas Uchyn
Vice President of Sales
PharmaForce, Inc.
960 Crupper Avenue
Columbus, Ohio 43229
614/436-2222
nuchyn@pharmaforceinc.com

PharmaForce, Inc. today received FDA approval for Progesterone Injection USP.

PharmaForce, Inc. today received FDA tentative approval for Zoledronic Acid Injection.

PharmaForce, Inc. today received FDA approval for Ciprofloxacin Ophthalmic Solution, USP.

PharmaForce, Inc. today received FDA approval for Fomepizole Injection.  The drug is a new generic available in the U.S.

PharmaForce, Inc. today received FDA approval for Phenytoin Sodium Injection, USP.

PharmaForce, Inc. was named the twelfth fastest growing company on the Business First Fast 50 List.  This is the fourth consecutive year PharmaForce has been eligible for nomination for The Fast 50, placing in the top 12 each year.

Honorees for the award were chosen from nominees submitted to Business First.  Rankings are based on the most recent three years' financial data for each company.  Privately held companies based in Central Ohio with more than $1 million in annual sales are eligible for the award.

PharmaForce, Inc. has launched commercial manufacturing operations at their sterile pharmaceutical facility located in Hilliard, Ohio.  The 40,000 square foot facility will house manufacturing of many of PharmaForce's approved drug products.

PharmaForce, Inc. today received FDA approval for Buprenorphine Hydrochloride Injection.

PharmaForce, Inc. was named the fifth fastest growing company on the Business First Fast 50 Awards.  This is the third consecutive year PharmaForce has made the top 10 on the Business First Fast 50 list.

Honorees for the award were chosen from nominees submitted to Business First. Rankings are based on the most recent three years’ financial data for each company. Privately held companies based in Central Ohio with more than $1 million in annual sales are eligible for the award.

PharmaForce, Inc. received FDA approval of the first generic formulations of Caffeine Citrate Injection and Oral Solution for commercial sale in the U.S.

PharmaForce, Inc. received FDA approval for Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension.

PharmaForce, Inc. announced the purchase of a 20,000 square foot facility in north Columbus.  This facility will allow for expanded pharmaceutical manufacturing activities and continues to expand PharmaForce operations in the Columbus, Ohio area.  With this purchase, PharmaForce now has over 80,000 square feet of pharmaceutical development and manufacturing space.